Skip to main content

Clinical Trials › NCT05269004

Active, Not RecruitingPhase 3

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis

Sponsored by Hoffmann-La Roche

Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov
1300
Target enrollment
26
U.S. states
May 2022
Start date
Dec 2027
Expected completion

Interventions / Treatments

Ocrelizumab

Conditions studied

Multiple Sclerosis

Where this trial is running (50 sites)

Florida5 sites
Maitland · Miami · Orlando · +2 more
California4 sites
Laguna Hills · Palo Alto · San Francisco · +1 more
Charlotte · Charlotte · Charlotte · +1 more
Texas4 sites
Houston · Houston · Lubbock · +1 more
Michigan3 sites
Detroit · Detroit · Farmington Hills
Arizona2 sites
Phoenix · Phoenix
Colorado2 sites
Aurora · Fort Collins
Illinois2 sites
Chicago · Northbrook
Minnesota2 sites
Golden Valley · Minneapolis
New Jersey2 sites
Newark · Teaneck
New York2 sites
Patchogue · Stony Brook
Ohio2 sites
Cincinnati · Westerville
Tennessee2 sites
Cordova · Knoxville
Washington2 sites
Seattle · Tacoma
Georgia1 site
Atlanta
Indiana1 site
Indianapolis
Kansas1 site
Kansas City
Boston
Missouri1 site
St Louis
Nebraska1 site
Omaha
Albuquerque
Oklahoma1 site
Oklahoma City
Oregon1 site
Portland
Abington
Providence
Vermont1 site
Burlington

Participating MS centers on MS Buddy (31)

MS centers in Florida

Compare treatment centers near a trial site by center type, providers and trials.

View Florida centers

More Phase 3 trials

Browse all Phase 3 MS trials
The app

Check out the MS Buddy app

Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.

Download on the App StoreGet it on Google Play